Bio-Techne Corp
TECH65.700USD
+1.120+1.73%
Fechamento 01/09, 16:00（ET）Cotações atrasadas em 15 min
10.23BValor de mercado
131.56P/L TTM
Mais detalhes de Bio-Techne Corp Empresa
Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.
Informações de Bio-Techne Corp
Código da empresaTECH
Nome da EmpresaBio-Techne Corp
Data de listagemFeb 09, 1989
CEOKelderman (Kim)
Número de funcionários3100
Tipo de títulosOrdinary Share
Fim do ano fiscalFeb 09
Endereço614 Mckinley Pl N E
CidadeMINNEAPOLIS
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal55413
Telefone16123798854
Sitehttps://www.bio-techne.com/
Código da empresaTECH
Data de listagemFeb 09, 1989
CEOKelderman (Kim)
Executivos da empresa Bio-Techne Corp
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+1640.00%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Mr. David Clair
Mr. David Clair
Investor Relations
Investor Relations
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+1640.00%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-2303.00%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+1640.00%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+1640.00%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+1640.00%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+1640.00%
Detalhamento da receita
Moeda: USDAtualizado em: ter, 6 de jan
Moeda: USDAtualizado em: ter, 6 de jan
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
Por RegiãoUSD
Nome
Receita
Proporção
United States
155.24M
54.17%
EMEA, excluding U.K
65.13M
22.73%
Greater China
24.79M
8.65%
APAC, excluding Greater China
19.15M
6.68%
United Kingdom
13.21M
4.61%
Rest of World
9.05M
3.16%
Por Empresa
Por Região
Por EmpresaUSD
Nome
Receita
Proporção
Consumables
231.60M
80.82%
Service
27.48M
9.59%
Instruments
21.83M
7.62%
Royalty
5.65M
1.97%
Distribuição de ações
Atualizado em: dom, 16 de nov
Atualizado em: dom, 16 de nov
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Outro
72.73%
Investidores
Investidores
Proporção
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Outro
72.73%
Tipos de investidores
Investidores
Proporção
Investment Advisor
58.57%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.06%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.35%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
1201
167.79M
107.68%
+389.22K
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
17.89M
11.48%
-504.17K
-2.74%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.64%
-7.47K
-0.08%
Sep 30, 2025
State Street Investment Management (US)
5.75M
3.69%
-105.19K
-1.80%
Sep 30, 2025
Wellington Management Company, LLP
5.12M
3.28%
+3.98M
+349.84%
Sep 30, 2025
Atlanta Capital Management Company, L.L.C.
4.94M
3.17%
+646.77K
+15.06%
Sep 30, 2025
Geode Capital Management, L.L.C.
4.93M
3.16%
+864.67K
+21.28%
Sep 30, 2025
Invesco Capital Management LLC
3.51M
2.26%
+275.06K
+8.49%
Sep 30, 2025
Neuberger Berman, LLC
3.31M
2.12%
+807.15K
+32.29%
Sep 30, 2025
T. Rowe Price Associates, Inc.
3.12M
2%
-5.50M
-63.78%
Sep 30, 2025
Maverick Capital, Ltd.
3.01M
1.93%
+3.01M
--
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
Global X Genomics & Biotechnology ETF
4.29%
Invesco Biotechnology & Genome ETF
2.92%
Invesco S&P 500 Equal Weight Health Care ETF
2%
Neuberger Berman Small-Mid Cap ETF
1.78%
VanEck Biotech ETF
1.73%
Hilton Small-MidCap Opportunity ETF
1.7%
iShares Health Innovation Active ETF
1.68%
American Century Mid Cap Growth Impact ETF
1.47%
Thrivent Small-Mid Cap ESG ETF
1.34%
Invesco S&P 500 High Beta ETF
1.06%
Ver Mais
Global X Genomics & Biotechnology ETF
Proporção4.29%
Invesco Biotechnology & Genome ETF
Proporção2.92%
Invesco S&P 500 Equal Weight Health Care ETF
Proporção2%
Neuberger Berman Small-Mid Cap ETF
Proporção1.78%
VanEck Biotech ETF
Proporção1.73%
Hilton Small-MidCap Opportunity ETF
Proporção1.7%
iShares Health Innovation Active ETF
Proporção1.68%
American Century Mid Cap Growth Impact ETF
Proporção1.47%
Thrivent Small-Mid Cap ESG ETF
Proporção1.34%
Invesco S&P 500 High Beta ETF
Proporção1.06%
Dividendo
Um total de
250.90M
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Nov 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 28, 2025 going ex on Nov 17, 2025
Nov 17, 2025
Nov 28, 2025
Nov 17, 2025
Aug 06, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 29, 2025 going ex on Aug 18, 2025
Aug 18, 2025
Aug 29, 2025
Aug 18, 2025
May 07, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 30, 2025 going ex on May 19, 2025
May 19, 2025
May 30, 2025
May 19, 2025
Feb 05, 2025
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
Ver Mais
Desdobramento de ações
Data
Tipo
Proporção
Nov 01, 2022
Split
1→4
Data
Tipo
Proporção
Nov 01, 2022
Split
1→4
Perguntas frequentes
Quem são os cinco principais acionistas de Bio-Techne Corp?
Os cinco principais acionistas de Bio-Techne Corp são:
The Vanguard Group, Inc. detém 17.89M Ações, representando 11.48% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 8.79M Ações, representando 5.64% do total de Ações.
State Street Investment Management (US) detém 5.75M Ações, representando 3.69% do total de Ações.
Wellington Management Company, LLP detém 5.12M Ações, representando 3.28% do total de Ações.
Atlanta Capital Management Company, L.L.C. detém 4.94M Ações, representando 3.17% do total de Ações.
The Vanguard Group, Inc. detém 17.89M Ações, representando 11.48% do total de Ações.
BlackRock Institutional Trust Company, N.A. detém 8.79M Ações, representando 5.64% do total de Ações.
State Street Investment Management (US) detém 5.75M Ações, representando 3.69% do total de Ações.
Wellington Management Company, LLP detém 5.12M Ações, representando 3.28% do total de Ações.
Atlanta Capital Management Company, L.L.C. detém 4.94M Ações, representando 3.17% do total de Ações.
Quais são os três principais tipos de acionistas de Bio-Techne Corp?
Os três principais tipos de acionistas da Bio-Techne Corp são:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
Quantas instituições possuem ações da Bio-Techne Corp (TECH)?
Em 2025Q4, 1201 instituições possuíam ações da Bio-Techne Corp, com valor de mercado aproximado de 167.79M, representando 107.68% do total de ações. Em comparação com 2025Q3, a participação institucional aumentou em 4.16%.
Qual é a maior fonte de receita da Bio-Techne Corp?
Em FY2026Q1, o segmento de negócios Consumables gerou a maior receita para Bio-Techne Corp, totalizando 231.60M e representando 80.82% da receita total.
